

Asian Journal of Research in Pharmaceutical Sciences and Biotechnology



Journal home page: www.ajrpsb.com

MOLECULAR DOCKING STUDIES OF PHYTOCHEMICAL COMPOUND TARGETING AGAINST BREAST CANCER AND SYSTEMS BIOLOGY

G. Sandhiya*¹, G. Bhuvaneshwari¹, B. Aarthi Rashmi¹, M. Vidya¹, S. Jeeva Bharathi¹

^{1*}Department of Bioinformatics, Sri Krishna Arts and Science College, Coimbatore-641008, India.

ABSTRACT

Breast cancer occurs when cells in breast tissue mutate and keep dividing. These abnormal cells form a tumor. A tumor is said to be malignant when these invade other parts of the breast. Up to 10% of all breast cancers are thought to be inherited, and most of the cases are due to defects in one or more genes, especially the BRCA1 or BRCA2 gene. The Breast Ovarian Cancer-1 BROVCA1 can be caused by mutation in BRCA1 gene on chromosome 17y. The genes confer cellular phenotypes consistent with a role in tumor formation. Different terms are applied in this area including computer aided drug designing, insilico drug design. Targeting Bcl2 family members become an important and attractive approach towards cancer therapy. In different malignancies the Bcl2 family proteins and Bcl2 like proteins are compound of anti-apoptotic machinery and are over expressed.

KEYWORDS

BRCA1, BRCA2 gene, BROVCA3, Mutation, Bcl2 and Insilico drug design.

Author for Correspondence:

Sandhiya G,

Department of Bioinformatics,

Sri Krishna Arts and Science College,

Coimbatore-641008, India.

Email: sandhiya28598@gmail.com

Available online: www.uptodateresearchpublication.com

INTRODUCTION

Breast cancer occurs when cells in breast tissue mutate and keep dividing. These abnormal cells form a tumor. A tumor is said to be malignant when these invade other parts of the breast or metastasize to other areas of the body through the bloodstream or lymphatic system, a network of vessels and nodes within the body that plays a task in fighting infection. Up to 10% of all breast cancers are thought to be inherited, and most of the cases are due to defects in one or more genes, especially the BRCA1 or BRCA2 genes. Breast-ovarian cancer-1 BROVCA1 can be caused by mutation in the BRCA1 gene on chromosome 17q, BROVCA2 by

mutation in the BRCA2 gene on chromosome 13q12, BROVCA3 by mutation in the RAD51C gene on chromosome 17q22, and BROVCA4 by mutation in the RAD51D gene on chromosome 17q11. Furthermore, the PPM1D gene on 17q is commonly amplified in breast cancer and appears to lead to cell transformation by abrogating p53 tumor suppressor activity. Some genomic regions have been found to be amplified in breast cancer, including 8q24, 20q13, 11q12, and 8p12-p11².

The NCOA3and ZNF217 genes, located on 20q, undergo amplification in breast cancer; when over expressed, these genes confer cellular phenotypes consistent with a role in tumor formation³. In humans, six ant apoptotic members of the Bcl-2 family have been identified (Bcl-2, Bcl-xL, Bcl-B, Bcl-W, Bfl-1, and Mcl-1), in which Bcl-2 family proteins and Bcl-2 like proteins are a component of the anti-apoptotic machinery and are over expressed in different malignancies. Therefore, targeting Bcl-2 family members becomes an important and attractive approach towards cancer therapy. Use of computational techniques in drug discovery and development process is rapidly gaining in popularity, implementation and appreciation. Different terms are being applied to the current space, including computer-aided drug design (CADD), computational drug design, computeraided molecular design (CAMD), computer-aided molecular modeling (CAMM), rational drug design, in silico drug design, computer-aided rational drug design.

Apoptotic regulators

Apoptosis regulated is а cellular suicide mechanism. The central regulator of the apoptosis is the Caspases. Apoptotic proteins can be categorized into two broad categories: those that modulate mitochondrial function and those that regulate the activation of caspases responsible for activation and execution of the apoptotic cascade. These proteins are involved in regulation of the intrinsic, mitochondrial apoptotic pathway. Protein BID is cleaved by the activation of pro-caspase-8 through the extrinsic pathway, and translocate to the mitochondrion to promote cytochrome C release. Apoptosis is additionally regulated by numerous signal transduction pathways, possibly through

Available online: www.uptodateresearchpublication.com

post-translational modifications in BCL-2 family proteins.

BID Protein

The anti-apoptotic protein Bcl-2, bind BID and inhibit BID's ability to activate Bax. As a result, the anti-apoptotic proteins Bcl-2 inhibit apoptosis by sequestering BID, leading to reduced Bax activation. The expression of BID is up regulated by the tumor suppressorp53, and BID has been shown to be involved in p53-mediated apoptosis.

Gene information

Full Name-BH3 interacting domain death agonist Gene type-protein coding

Organism- Homo sapiens

Aim and Objective

The aim of the present study is by using a new antiapoptotic BID subfamily targeting the Breast cancer using the Discover studio 2.0 software.

- To find a new target for Breast cancer.
- To find a new drugs for treating Breast cancer
- To perform molecular docking using Discovery studios 2.0

MATERIAL AND METHODS

Swiss Model- A fully automated protein homologymodeling server, accessible via the ExPASy web server, or from the program Deep View (Swiss Pdb-Viewer). The purpose of this server is to make protein modelling accessible to all life science researchers worldwide SWISS-MODEL is a fully automated protein structure.

Chem sketch- version 14.01

Chem Sketch Freeware is a drawing package that allows you to draw chemical structures including organics, organometallics, polymers, and Markush structures. It conjointly includes options like calculation of molecular properties (e.g., mass, density, molar bending etc.), second and 3D structure cleanup and viewing, practicality for naming structures (fewer than fifty atoms and three rings), and prediction of log P. The package version of Chem Sketch doesn't embody all of the practicality.

Swiss PDB viewer- version4.1

Swiss-Pdb Viewer (aka Deep View) is an application that provides a user friendly interface October – December 96

allowing to analyze several proteins at the same time. The proteins may be superimposed so as to deduce structural alignments and compare their active sites or the other relevant elements.

Discovery studios

Discovery Studio provides the most advanced modeling and simulation software solutions for life science researchers available today. From project conception to steer improvement, Discovery Studio includes a diverse collection of sophisticated software applications in a single, easy-to-use Linux-Windows-based environment. or Because Discovery Studio is built upon Pipeline Pilot platform, Accelrys scientific operating platform, any software that you need can be integrated into the research environment, whether it's from Accelrys, in-house developers, or other vendors to provide a truly customized solution.

Binding DB

It is a public, web-accessible database of measured binding affinities, focusing chiefly on the interactions of proteins considered to be candidate drug-targets with ligands that are small, drug-like molecules. Binding DB's web-interface provides a spread of browsing, query and data download tools. These embody browsing by the name of a macromolecule Target or by journal citation, query by chemical similarity and substructure, and downloads by target or query result.

Pub chem

Pub Chem may be an info of chemical molecules and their activities against biological assays. The system is maintained by the National Center for Biotechnology data (NCBI), a component of the National Library of Medicine, which is part of the United States National Institutes of Health (NIH). Pub Chem may be accessed at no cost through an online computer program. Millions of compound structures and descriptive datasets may be freely downloaded via FTP. Pub Chem contains substance descriptions and little molecules with fewer than one thousand atoms and one thousand bonds. More than eighty info vendors contribute to the growing Pub Chem info.

Uniprot

UniProt KB/Swiss-Prot may be a manually annotated, non-redundant protein sequence

Available online: www.uptodateresearchpublication.com

database. It combines data extracted from scientific literature and biocurator-evaluated process analysis. The aim of UniProt KB/Swiss-Prot is to produce all famed relevant data a few specific macromolecule. Annotation is often reviewed to stay up with current scientific findings. The manual associate degree notation of an entry involves elaborate analysis of the macromolecule sequence and of the scientific literature.

RESULTS AND DISSCUSION

Target selection

Target was selected based on the literature review. Anti-apoptotic protein BID was selected as the target.

New target identification by using comparative modeling

The protein sequence of BID was retrieved from UniProt and a new target was modeled using Swissmodel.

One model was generated and used as a target.

Structure Validation

The modeled protein was validated using swiss PDB viewer.

Ramachandran plot was generated and the proteins outside the allowed regions were dragged inside the allowed regions.

Ligand selection

Oxycodone is the common commercial drug used for treating breast cancer. A list of microbial ligands were taken based on the literature review.

Virtual screening of ligands

The ligands were screened against oxycodone using binding DB and the best ligand was choosed using the maximum smiliraity score.

Docking

One compound was selected based on the maximum similarity value and the compound was docked against the modeled protein.

Selected ligand (FDA approved Drug available commercially)- Oxycodone [Pub Chem ID: 5284603].

Protein or Receptor- BID [Uniprot ID: P10144].

Oxycodone was compared with the following phytochemical compounds and the maximum similarity value was found using Binding DB.

The selected compound among them is Catechin

(0.38) which had the maximum similarity value with oxycodone.

SYSTEMS BIOLOGY

Systems biology is the computational modeling of complex biological networks. It is a biology-based knowledge domain field of study that focuses on complicated interactions among biological systems. Systems biology allows one to develop data repositories, and tools for simulation, analysis and visualization of system components such as biochemical networks. It also enables High Throughput molecular profiling and signal procession.

SBML (Systems Biology Markup Language)

A standard language for representing biochemical reaction networks in Systems Biology. It is a software-independent language for describing models common to research in many areas of computational biology, including cell signaling pathways, metabolic pathways, gene regulation, and others.

Networks are able to link with simulation and other analysis packages through Systems Biology Workbench (SBW). It is a collection of tools which includes programs for building, viewing and editing biochemical networks. Also, consists of tools for simulation, import and translation of models.

Cell Designer

Cell Designer is a Java -based program for constructing and editing of Biochemical networks. Networks are drawn based on the process diagram, with Systems Biology Graphical Notation system and #40; SBGN and #41; proposed by Kitano, and are stored using Systems Biology Markup Language (SBML). Recent version can import models in SBML and support display of biochemical networks.

Introduction to cell designer

Cell Designer may be a structured diagram editor for drawing gene-regulatory and organic chemistry networks. Networks are drawn supported the method diagram; with graphical notation system. The file stored will be an xml file representing the SBML model structure. Main Window consists of Menu, Toolbars, and the five Areas as shown below.

Available online: www.uptodateresearchpublication.com

- Menu
- Toolbar
- Draw Area
- Tree Area
- Layer Area
- List Area
- Notes Area

PROTEIN KINASE PATHWAY

Protein kinases are enzymes that function by phosphorylating other proteins by chemically adding phosphate groups or codes. The codes instruct the cell to work, such as divide or grow. Phosphorylation is a common way of activating or inactivating enzymes and protein kinases are thus often found in signaling pathways.

KINASE PATHWAY

Kinase pathway is a chain of proteins in the cell that transfers a signal from a receptor present on the surface of the cell to the DNA in the nucleus of the cell. The signal starts when a signaling molecule binds to the receptor and ends when the DNA in the nucleus expresses a protein and produces some change in the cell. The pathway includes many proteins, including MAPK (mitogen-activated protein kinases) which communicate by adding phosphate groups to a neighboring protein, which acts as an "on" or "off" switch. When one of the proteins in the pathway is mutated, it can become stuck in the "on" or "off" position, which is a necessary step in the development of many cancers. The MAPKKK is typically activated by interactions with a small GTPase and/or phosphorylation by protein kinases downstream from cell surface receptors. Uncontrolled growth may be a necessary step for the event of all cancers. In many cancers, a defect in the MAP/ERK pathway leads to uncontrolled growth. Many compounds will inhibit steps within the MAP/ERK pathway, and therefore are potential drugs for treating cancer.

Kinase pathway generated using cell designer.

Gene switches

Some of the non-protein coding DNA regulates once and wherever genes are turned on and off and the way a lot of super molecule they turn out. The

regulative machinery works once proteins known as transcription factors bind to specific short sequences of polymer that flank the sequence, called transcription factor binding sites, and by doing so, switch genes on and off. Mutations to DNA sequences also play roles in turning genes on and off.

Lac operon pathway

The lac operon (lactose operon) is required for the transport and metabolism of lactose in E.coli. Although aldohexose is that the most well-liked carbon supply for many bacterium, the lac operon allows for the effective digestion of lactose when glucose is not available through the activity of beta-galactosidase. When disaccharide is needed as a sugar supply for the microorganism, the three genes of the lac operon can be expressed and their subsequent proteins translated: lacZ, lacY, and lac A.

If glucose is present, the lac operon uses a two-part control mechanism to ensure that the cell expends energy producing the enzymes encoded by the lac operon only when necessary. In the absence of disaccharide, the lac repressor, lacI, halts production of the enzymes encoded by the lac operon.

Gene expression

Gene expression is that the method by that sequencetic directions are accustomed synthesizes gene merchandise. These products are usually proteins, which go on to perform essential functions as enzymes, hormones and receptors. The process of gene expression includes the following steps:

Transcription, processing, non-coding RNA maturation, RNA export, translation and protein folding.

Table No.1: Ligands that are similar to Oxycodone and their maximum similarity score obtained from	
binding DB when screened	

S.No	Compound Name	Pubchem ID	Maximum similarity value
1	Catechin	9064	0.38
2	Terpenoid	3385	0.26
3	Gossypol	3503	0.22
4	Eremanthin	572	0.18
5	Coztunoloid	7559	0.17
6	Gallic Acid	370	0.14
7	Octylgallate	1253	0.2
8	Saponin	7422	0.2
9	Lupeol	846	0.1

Table No.2: Table showing the results of BID protein docked against oxycodone

S.No	Absolute Energy of Catechin	Relative Energy of Catechin	LibDock score	Total No. of poses	H Bonds
1	30.971	0.506	107.119	38	383

Location: 22q11.21 Exon count: 8				See BID in <u>Genome Data Viewer</u>
Annotation release	Status	Assembly	Chr	Location
<u>109</u>	current	GRCh38.p12 (GCF_000001405.38)	22	NC_000022.11 (1773414017774665, complement)
<u>105</u>	previous assembly	GRCh37.p13 (GCF_000001405.25)	22	NC_000022.10 (1821690618257431, complement)
	[17562470 SL C25A	·		[17782193] NIR3196-1 - LOC106799035 - LINC00528 -

Figure No.1: location of the gene retrieved from NCBI

Available online: www.uptodateresearchpublication.com




Figure No.3: The new model generated in Swiss model was then opened in Discovery studio using. pdb file extension, the hetero atoms and water molecules were removed

Available online: www.uptodateresearchpublication.com




Figure No.4: The total number of active sites were viewed by defining the selected molecule as the receptor. The active site one was selected




Figure No.5: The virtual analysis of biomolecule inside a human body can be studied by defining them inside a grid in molecular modeling. Discovery studio uses sphere that was defined in the selected active site

Available online: www.uptodateresearchpublication.com

	Separate that	The second second second second	Contract of the second se			-	and the second	a				
IS PIG IS NO X Y	1011444			× 0 0.0		ole de la	204	5 :				
12+ 15-22 (Pr. 14 (PR. 1	2500	8	** ** .	0. 5. 7 .	É							
Nok = Potenik P	en 1 hErele	and incaring tiller pro-	nidenty (K) - meta	Infed - 300 Mile	aller	(Terper	nati - 30 window	- Dank	Openia (URDealt) - Here's	Altellan Contra	erfore - Table Browne	
				~								
Invitrio Sen					1-2-		IT	24				
Definition	1.1				1		7= -		11			
					. 1	le:	×.	Sent-				
Define Delected Molecule as Paragity	52 - E				1		V.Fr	Som.				
Define Sphere Intel Selection						Υ.	100	5	styr			
Find Sites from Assessing Cardina						~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	JABC	2				
Find Silves an Websher of Selected Uppe				10	1	. *	Mark Co	· Se				
Sile Editing	·*			2	1.	1.57	/ ~ ~~	1X-				
Contrait Briding Stee				1	1	V		A Far	TA.			
Expand Briding Sites				1		-	AL T	m St	LATK >	2-		
Deleta Briding Silas Punts				-ip-te	1	~	151-1	17	C	>-		
Partition Gen.				-	\mathcal{X}^{*}	-1	7-80	2 13	5/70			
	100			1	-	- Ale	a second	1777	A Sector	1-		
Converse? In Annual						I AT	201-	199=	Start L	-		
						- A - A - A - A - A - A - A - A - A - A	1.20					
Depley	- 11					$\mathcal{I}_{\mathcal{I}}$. CR	5-4-0				
	- 11				~	24	· R	× Kar	17			
Dight (Fandrich (da.))daran					1	1	· R	× Ka	4			
Depley (Forschule (de Spheres) Gales Depley Forschute (Forschule					1,	3	: K.		4			
Deplet Develop (in Space Cale Sector Product Party Space Second Product Space					1.	Y			4			
Depley (Forschule (de Spheres) Gales Depley Forschute (Forschule	_				5	Y		A.	4	1		
Deplet Develop (in Space Cale Sector Product Party Space Second Product Space	_	and the second sec	Nacus	2 des	Abunta	1+0	Cartheoter	Par-	10- MAL ALPREN	POSE_NEMBER	Ubbonuse	Iversuot
Deeley Developing Six Sylveen Construction Institute Journ Sylvee Sevenistic Facetain Construction Neuro Six Persona Six	_		9664	1	30.975		Cardhaster 8	0.506	12 102. Janes	PUTE_ALPHER	107.119	Heartpace
Depley Brendhein fein ligheren Cana Deputie Providien Deter Univer Strendhein Fanstein Dateit Spreise Beet Ste	_		9054 9,004	1	90.971 30.971	0+p		0.506		POR MPRO	107.119 106.681	10000100
Dealer Developing Six Spheres Com Souther Presiden Josef Sphere Strendsche Feisetaus Datate Sphere Nach Sie Preview Siz Herview Siz	1 2 3		9664 9,084 9,184	1	30.971 30.971 36.854	n=p	Carthadar a	0.505 0.506 6.300	1 1 1	PUDE_NEMICE 1 2 3	107.119 106.691 100.636	0.90,37 34
Deeley Developing Six Sylveen Construction Institute Journ Sylvee Sevenistic Facetain Construction Neuro Six Persona Six	_		9054 9,004	1	90.971 30.971		Carthadar	0.506	The MAX MARKER	Prote_NLPHICH 1 2 3 4	107.119 106.681	0.40,37.34
Dealer Developing Six Spheres Com Souther Presiden Josef Sphere Strendsche Feisetaus Datate Sphere Nach Sie Preview Siz Herview Siz	12.0		9664 9,084 9,184	1	30.971 30.971 36.854		Contribution 5 5 6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	0.506 0.506 6.308 6.308	P2- 103_54.94888	P008_Ne#808 1 2 3 4	107.119 106.691 100.636	0.40,37.34 2.10,19.35 7.00,31.74
Device Device (in provide the provident the providen	12.0		9664 9,084 9,184	1	90.971 30.971 36.404 9.464		S T B W W Quirds (J.McDeck)	0.506 0.506 6.308 6.308	rge 143, ALPERS 1 1 1 1 1 1 1 1 1 1 1 1 1	PCDE_NEARER 1 2 3 4	107.119 106.691 100.636	0.90.37.34 2.80.19.34 7.00.21.74
Deeley Develop (Development Constructive branches from lipher Shreehole franches from lipher Next Ste Prenas Ste Etternoloo Pflere Defree Interaction Ste Hally (Defre 2)		Elaport Teur	9664 5,014 5,014 5,014 5,014 5,014	1 1 1	30.571 30.871 36.654 9.494	Disk Li Parameter	S T B W W Quirds (J.McDeck)	0.506 0.506 6.308 6.308	4 19 10	1 2 3 4	107.119 106.691 100.636	0.90.37.34 2.80.19.34 7.00.21.74
Device Drawfrain (dir lipfwww) Cam Drawfrain (dir lipfww) Drawfrain Powatan Dutam Sphere Newtaus Ste Pervisus Ste Pervisus Ste Dafwe Interaction Ste Hele Data & Peter Star		Eliquent Terrer	9004 9,004 9,304 9,904 9,904 9,000 9,0000 9,0000 9,0000000000	2 2 8 9	30.971 30.971 30.971 30.971 30.971 30.971	Disk Li Parameter	5 5 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	0.506 0.506 6.308 6.308	A 3 1 1	P028_NE#8800 1 2 3 4	107.119 106.691 100.636	0.90.37.34 2.80.19.34 7.00.21.74
Dealer Dealer (Se Sphere) Con Dealer Headan Dealer Sphere Service Readan Dealer Sphere Netter Sta Person Sta Defen alter Pflere Defen (Se Sphere) Head (Se Sphere) Person Status Defen (Secon) Secon)	*1	Eliqued Tree 1 5-15 36 6 0 14 15	9564 5,064 5,384 5,984 5,984 5,984 5,984 75,494 10,494 10,494 10,494 10,194 10,	1 2 4 *	20.571 30.871 36.894 9.499	Disch Lo Parameter Sysuit P Shipod L	5 5 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	0.506 0.506 6.308 6.308	A 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	1	107.119 106.691 100.636	0.90,17.34 2.80,19.34 7.00,21.74
Dealer Drawfinks (die lijdween Cars Steature Presidies Frank lijder Strawfinke Frankrac Datum Schwee Next Ste Perstass Site Etheraction Pillers Dafwe Interaction Site Petitischeren Status Dod Lijder Schwee Status Dod Lijder Schwee Status	toosen teopora	ESeptent Terrer 5 5x15 30 cd, 10 14 115 col 5 x14	9004 9,004 9,304 9,304 9,564 1,6664 1,6664 1,6664 1,6664 1,66664 1,66664 1,6666666666	1 2 3 4 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	90.575 30.875 36.874 9.4749 9.47	Disk to Parameter Syst 9 Syst 1 Broad 3	5. 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	0.506 0.506 6.308 6.308	A 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	1	107.119 106.691 100.636	0.90,17.34 2.80,19.34 7.00,21.74
Dealer Drandhals (die Upfanze) Calls Drandhe Freislahe Freislahe Strandhale Freislahe Freislahe Strandhale Freislahe Herrine schoo Pillen I Dafrie Internetion State Peter schoo Pillen I Dafrie Internetion State Peter School (School) Scores State Lagente (Léfocol) Scores	Detais Paperson 1, 2mm 12 poses terpers 12 poses terpers 14 poses terpers	Ellipsont Time 5 Social 20 6 Social 20 6 Social 20 6 Social 20 5	USA 2,004 5,304 5,304 5,304 1,5488 1,548 1,5488 1,5488 1,5488 1,548888 1,54888888888888888888888888888888888	1 2 4 * * * * * * * * * * * * * *	SO SPI SO	Disk to Parameter Signal 9 Signal 1 Brood 3 Number	5 5 8 9 9 9 9 9 9 9 9 9 9 9 9 9	0.506 0.506 6.308 6.308	1 3 9 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9 1 9	1	107.119 106.691 100.636	0.90,17.34 2.80,19.34 7.00,21.74
Deeley Drawlink (dir (plawer Cars Souther Freedor Drawn Sphere Showhile Freedor Drawn Sphere New Sie Premes Sile Harr schoo Pflers Dafner John Kell (Souther Halp Sele (Souther) Halp Sele (Souther) Halp Sele (Souther) South capacity (Solicol) Success Sock capacity (Solicol) Success Sock capacity (Solicol) Success	• • • • • • • • • • • • • • • • • • •	Elapsed Tense 5 5/15/36 d, 0.14/15 of 6/16/14 of 0.01/16 e, 0.021/46	9564 9,084 9,084 9,064 9,064 104,064 9 104,064 9 104,064 9 104,064 10 104,064 10 100,064 10 100,064 100,066 100,066 100,066 100,066 100,066 100,066 100,066 10	1 2 3 4 1 1 1 1 1 1 1 1 1 1 1 1 1	50.571 50.871 50.874 50.874 50.874 50.874 50.874 50.874 50.874 50.874 50.874 50.871 50.971 50.971 50.871 50	Disk Li Parameter Srpst I Srpst I Srpst J Stanler District	S. S. B. B. Manne Naropco Agandi Ste Sphere e of Hotgots g Tolerance	0.506 0.506 6.308 6.308	1 1 1 1 1 1 1 1 1 1 1 1 1 1	1	107.119 106.691 100.636	0.90,17.34 2.80,19.34 7.00,21.74
Dealer De	Eletals 72 posers tarpeno 14 posers tarpeno 16 posers tarpeno 16 posers tarpeno 16 posers tarpeno	Elepted Teer 5 0.05.96 (d) 0.14 (10) of 0.08 (14) of 0.08.19 (d) 0.03.96 (c) 0.03.196 (c) 0.03.196	9564 9,064 9,064 9,064 9,064 104,06410,066 104,066 104,06610,066 104,066 104,06610,066 100,066 100,066 100,066100,066 100,	1 2 3 4 4 7 d < Documenta 2 d < Documenta 2 d < Documenta 1 d < Documenta 1 d < Documenta	20.571 30.871 30.874 9.874 9.874 9.874 9.874 9.874 9.874 9.874 9.874 9.874 9.874 9.874 9.874 9.874 9.874 9.874 9.875 9.7557 9.755 9.7557 9.7557 9.7557 9.7557 9.7557 9.7557 9.7557 9	Direk Lo Parameter Syst i Syst i Narder Doctor 1 Doctor	5 5 9 9 9 9 9 9 9 9 9 9 9 9 9	0.506 0.506 6.308 6.308	8 8 9 Parasenter Value Parasenter Value Par	1	107.119 106.691 100.636	0.90,17.34 2.80,19.34 7.00,21.74
Deales Dealer (Dealer Feedale Free Infer Dealer Feedale Feedale Free Infer Dealer Ste Feedale Ste Feedale Ste Protect Feedale Infer Police (Dealer Infer Deal Light (ECOS) Sectors Deal Light (ECOS) Sect	Catal 2	Elepted Teer 5 0.05.96 (d) 0.14 (10) of 0.08 (14) of 0.08.19 (d) 0.03.96 (c) 0.03.196 (c) 0.03.196	9064 8,004 9,004 9,004 9,004 104,002 104,002 104,004 100,004 100,0000000000	1 2 3 4 4 7 II C Documents 2 IV C Documents	50.591 30.971 30.971 30.974 30.974 30.974 30.974 30.974 30.974 30.974 30.974 30.971 30	Deck of Far another Singlet F Singlet F North S North S Doctors Doctors Doctors Doctors Doctors Doctors	5 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	0.506 0.506 6.308 6.308	1 1 1 1 1 1 1 1 1 1 1 1 1 1	1	107.119 106.691 100.636	0.90.37.34 2.80.19.34 7.00.21.74
Dealer	Entails 72 posers 1, 2mm 12 posers 1, 2mm 10 posers trapper 10 posers trapper	Elipsent Tree 1. 5055.36 d, 0.014135 d5.00146 elipse136 elips	9064 9,004 9,004 9,004 9,004 104,1092 (24 10) 104,1092 (24 10) 104,1002 (2	1 2 3 4 4 4 4 4 4 4 4 4 4 4 4 4	00.971 30.971 30.971 30.974 30.974 30.974 30.974 30.974 30.974 30.974 30.9711 30.9711 30.9711 30.9711 30.9711 30.9711 30.9711 30	Deck of Parameter Syst 4 Syst 4 Syst 2 Name Dodars Dodars Dodars Dodars Dodars Dodars Dodars Dodars	5 5 7 8 8 9 7 4 4 4 4 4 5 9 5 9 5 9 5 9 5 9 5 9 5 9 5	0.506 0.506 6.308 6.308	1 3 3 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	1	107.119 106.691 100.636	0.90.37.34 2.80.19.34 7.00.21.74
Declar Decidation (dia lipfaceae Cara Decidic Resolution Front lipface Develoption Frontiane Datates Sphere Netto Sile Peterson Sile Pe	Eletak 20 pomer 1, hve Rosen kepters Biperer tenjers Biperer tenjers Biperer tenjers Biperer tenjers Biperer tenjers Biperer tenjers	Elapsed Teers 5 505:36 6 0:14 13 60 0:00 14 60 0:00 14 60 0:00 14 60 0:00 14 60 0:00 16 60 0:00 16 60 0:00 16	9064 8,004 9,004 9,004 9,004 174,1442,24 50 164 May 15 56 164 May 15 56 164 May 15 56 164 May 15 16 164 May 15 17 174 May 13 175 174 May 13 175	1 2 3 4 4 Comput Society 4 1 (Comput Society 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		Deck of Parameter Syst 4 Syst 4 Syst 2 Name Dodars Dodars Dodars Dodars Dodars Dodars Dodars Dodars	5 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	0.506 0.506 6.308 6.308	8 8 9 Parasenter Value Parasenter Value Par	1	107.119 106.691 100.636	0.90.37.34 2.80.19.34 7.00.21.74

Figure No.6: The best ligand to xycodone was uploaded to the active site




Figure No.7: Final results of docking

Available online: www.uptodateresearchpublication.com






Figure No.8: Created using mindmup software




Figure No.9: Outline of cell designer




Figure No.10: Kinase pathway constructed using Cell Designer where the rectangles represent proteins, dotted lines represent the complex, circles represent phosphate groups

103

Available online: www.uptodateresearchpublication.com October – December







Figure No.11: Lac operon pathway






Figure No.12: Gene expression

Available online: www.uptodateresearchpublication.com

THEPATHWAY OF PROTEIN KINASE WAS GENERATED USING CELL DESIGNER BASED ON KINETIC LAW




Figure No.13: Bio Med ID- 26




Figure No.14: Kinetic law of reactions was modified according to the instructions

Species	Proteins	Genes RNAs as	RNAs Reactions	Compartme	ents Parame	eters Functions L	InitDefinitions	Rules Events S	peciesTy	pes Com	partmen	tTypes	InitialAssignments	Constraints
						Edit	Export							
class	id	name	speciesType	compar	position	included	quantit	initialQuantity	sub	has0	b.c.	c		
PROTEIN	M	м		uVol	transme		Amount	500.0	1	false	false	false		
PROTEIN	Mp	Мр		uVol	transme		Amount	0.0		false	false	false		
PROTEIN	Mpp	Мрр		uVol	transme		Amount	0.0		false	false	false		E
PROTEIN	MAPKK	MAPKK		uVol	transme		Amount	100.0		true	false	false		
PROTEIN	MKP3	MKP		uVol	transme		Amount	100.0		false	false	false		
PROTEIN	M_M	M_MAPKK		uVol	transme		Amount	0.0		false	false	false		
PROTEIN	Mp	Mp_MAPKK		uVol	transme		Amount	0.0		false	false	false		-

Figure No.15: Initial values

Available online: www.uptodateresearchpublication.com

Species	23
id	MKP3
name	MKP
speciesType	
compartment	uVol
initial	Amount
	50.0
substanceUnits	✓
hasOnlySubstanceUnits	(a) true (c) false
boundaryCondition	⊚ true
constant	⊚ true
Upda	te <u>C</u> ancel

Figure No.16: Updating the initial values

Edit Export dass id name speciesType compar position induded quantit initialQuantity sub hasO b.c. c PROTEIN M M uVol transme Amount 500.0 false	A 4																1
id name speciesType compar position induded quantit initialQuantity sub hasO b.c. c.m. PROTEIN M M uVol transme Amount 500.0 false	Species	Proteins	Genes RNA	s asRNAs	Reactions	Compartme	nts Param	eters Functions	UnitDefinitions	Rules Ev	vents	SpeciesTy	pes Co	ompartme	ntTypes	InitialAssignments	
PROTEIN M M M uVol transme Amount 500.0 false false false PROTEIN Mp Mp uVol transme Amount 0.0 false false false PROTEIN Mpp uVol transme Amount 0.0 false false false PROTEIN MAPKK uVol transme Amount 0.0 false false PROTEIN MAPKK uVol transme Amount 100.0 true false PROTEIN MR3 MKP uVol transme Amount 50.0 true false PROTEIN M_M M_MAPKK uVol transme Amount 0.0 false false								Edit	Export								
PROTEIN M M uVol transme Amount 500.0 false false false PROTEIN Mp Mp uVol transme Amount 0.0 false false false PROTEIN Mp Mp uVol transme Amount 0.0 false false false PROTEIN MAPKK uVol transme Amount 100.0 true false false PROTEIN MR3 MKP uVol transme Amount 50.0 true false false PROTEIN M_M M_MAPKK uVol transme Amount 50.0 true false false	class	id	name	SDE	eciesType	compar	position	included	quantit	initialQuant	titv	sub	has0	b.c.	C		-
PROTEIN Mpp Mpp uVol transme Amount 0.0 false false false PROTEIN MAPKK MAPKK uVol transme Amount 100.0 true false false PROTEIN MKP3 MKP uVol transme Amount 50.0 true false false PROTEIN M_M M_MAPKK uVol transme Amount 50.0 true false false	PROTEIN	_								-	,						
PROTEIN MAPKK MAPKK uVol transme Amount 100.0 true false false PROTEIN MKP3 MKP uVol transme Amount 50.0 true false false PROTEIN M_M M_MAPKK uVol transme Amount 50.0 true false false PROTEIN M_M M_MAPKK uVol transme Amount 0.0 false false	PROTEIN	Mp	Мр			uVol	transme		Amount	0.0			false	false	false		
PROTEIN MKP3 MKP uVol transme Amount 50.0 true false <	PROTEIN	Mpp	Мрр			uVol	transme		Amount	0.0			false	false			
PROTEIN M_M M_MAPKK uvol transme Amount 0.0 false false false	PROTEIN	MAPKK	MAPKK			uVol	transme		Amount	100.0			true	false	false		
	PROTEIN	MKP3	МКР			uVol	transme		Amount	50.0			true				
PROTEIN Mp Mp_MAPKK uVol transme Amount 0.0 false false false	PROTEIN	M_M	M_MAPKK			uVol	transme		Amount	0.0			false				
	PROTEIN	Mp	Mp_MAPKK			uVol	transme		Amount	0.0			false	false	false		




Figure No.17: Modified values

Figure No.18: Graph generated for the pathway- biomed id 26using cell Designer

Available online: www.uptodateresearchpublication.com

CONCLUSION AND SUMMARY

The present study helps us to understand the interaction between the ligand Oxycodone and receptor BID protein and also explore their binding mode. Docking study was performed using Discovery Studios 2.1. The protein structure was modeled from Swiss-Model and used as a target for docking simulation shown in Figure No.3 -7. The compounds selected from the literature and screened against oxycodone using Binding DB are listed in Table No.1. Ligand were created and prepared for the docking procedure using Chem Sketch and SPDBV.

- Ligand Catechin and modelled BID protein as receptor were taken to explore their binding mode. Docking study was performed using Discovery Studios 2.1.
- It is found that the binding affinity of phytochemical compound oxycodone against the modelled protein is 30.972 Kcal/mol.
- This work evaluates the binding efficiency and the counteraction with the modelled protein.

The Protein-Ligand interaction plays a significant role in ligand based designing. In the present work we have taken the receptor that is modelled from Swiss-model and identified a bioactive phytochemical compound. When the receptor was docked with the ligand, the energy value obtained was (-30.971 kcal/mol) using Discovery Studios 2.1.From this we conclude that the phytochemical compound catechin obtained from literature review can be taken to further drug developmental studies.

In this study, the molecular docking was applied to explore the binding mechanism and to correlate its docking score with the activity of plant derived compounds. The results of our present study can be useful for the design and development of novel compounds having better inhibitory activity against breast cancer. This potential agent will be a promising candidate that can further be validated in wet lab studies for its proper function. In future research work the ADMET (Absorption, Distribution, Metabolism, and Excretion, Toxicity) properties of these compounds can be tested in wet lab and research can proceed for clinical trials.

ACKNOWLEDGEMENT

The authors wish to express their sincere gratitude to Department of Bioinformatics, Sri Krishna Arts and Science College, Coimbatore-641008, India for providing necessary facilities to carry out this research work.

CONFLICT OF INTEREST

We declare that we have no conflict of interest.

BIBLIOGRAPHY

- 1. Bulavin D V, Demidov O N, Saito S, Kauraniemi P, Phillips C, Amundson S A, Ambrosino C, Sauter G, Nebreda A R, Anderson C W, Kallioniemi A, Fornace A J, Appella E. Amplification of PPM1D in human tumors abrogates p53 tumorsuppressor activity, *Nature Gene*, 31(2), 2002, 210-215.
- Yang Z Q, Streicher K L, Ray M E, Abrams J, Ethier S P. Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer, *Cancer Res*, 66(24), 2006, 11632-11643.
- Collins C, Rommens J M, Kowbel D, Godfrey T, Tanner M, Hwang S, Polikoff D, Nonet G, Cochran J, Myambo K, Jay K E, Froula J and Thomas Cloutier, Wen-Lin Kuo, Paul Yaswen, Shanaz Dairkee, Jennifer Giovanola, Gordon Hutchinson B, Jorma Isola, Olli-P Kallioniemi, Mike Palazzolo, Chris Martin, Cheryl Ericsson, Dan Pinkel, Donna Albertson, Wu-Bo Li, and Joe Gray W. Positional biological research of ZNF217 and NABC1: genes amplified at 20q13.2 and over expressed in breast cancer, *Proc. Nat. Acad. Sci*, 95(15), 1998, 8703-8708.

Please cite this article in press as: Sandhiya G *et al.* Molecular docking studies of phytochemical compound targeting against breast cancer and systems biology, *Asian Journal of Research in Pharmaceutical Sciences and Biotechnology*, 6(4), 2018, 95-107.

Available online: www.uptodateresearchpublication.com